


The following listing of claims set forth replace all prior versions and listings of claims in the application.

# IN THE CLAIMS

1. (currently amended) A compound of Formula I:



Formula I

a pharmaceutically acceptable salt or stereoisomer thereof,

wherein

X is N(CH<sub>3</sub>) or O;

R<sub>1</sub> is OH or C<sub>1-6</sub> alkoxy;

R<sub>2</sub> is H or C<sub>1-6</sub> alkyl;

R<sub>3</sub> is (CH<sub>2</sub>)<sub>n</sub> Q, CH<sub>2</sub>CH(OH)Q, CH(CH<sub>3</sub>)Q, 1,2,3,4-tetrahydronaphthyl, indanyl, or adamantyl, wherein

Q is thienyl, phenyl, or furanyl, naphthyl, pyridyl, indolyl, indazolyl, cyclohexyl, 1,2-methylenedioxyphenyl, cyclohexenyl, 1H-pyrazolo[4,3-c]pyridyl, and

Q is optionally substituted with one or two moieties independently selected from halo, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxy, hydroxy, S(O)<sub>2</sub>NH<sub>2</sub>, trifluoromethyl, or cyano, and

n is 1 or 2; and

R<sub>4</sub> is H or C<sub>1-6</sub> alkyl; or

~~R<sub>3</sub> and R<sub>4</sub> together with the nitrogen atom to which R<sub>3</sub> and R<sub>4</sub> are attached, form 1,4-dioxo 8-azo spiro[4.5]decanyl, piperaziny, morpholinyl, piperidinyl, pyrrolidinyl, azocanyl, 1,2,3,4-tetrahydroisoquinolinyl, 1,2,3,4-tetrahydro-β-carbolinyl, 4,5,6,7-tetrahydrothienyl[3,2-c]pyridyl, or 8-aza bicyclo[3.2.1]octane, each of which may be mono or independently di-substituted with halo, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxy, C(O)phenyl, OH, CN, O-phenyl or (CH<sub>2</sub>)<sub>n</sub> Z,~~

Z is benzisoxazolyl, indazolyl, benzisothiazolyl, benzothienyl, pyrimidinyl, pyridyl, 1,2-methylenedioxyphenyl, or phenyl, and

~~Z, CH(OH)phenyl or O-phenyl are optionally substituted with one or two moieties independently selected from halo, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxy, hydroxy, trifluoromethyl, S(O)<sub>2</sub>NH<sub>2</sub>, or cyano, and~~

~~m is 0 or 1;~~

~~provided that when R<sub>1</sub> is OH, R<sub>2</sub> is H;~~

- ~~(1) R<sub>4</sub> is H, and R<sub>3</sub> is (CH<sub>2</sub>)<sub>n</sub>Q, where n is 1 or 2, then Q cannot be indolyl or phenyl; or~~
- ~~(2) R<sub>3</sub> and R<sub>4</sub> form piperazinyl substituted with (CH<sub>2</sub>)<sub>m</sub>Z, when m is 1, then Z cannot be phenyl.~~
2. (currently amended) A compound according to claim 1 wherein Q is thienyl or ~~pyridyl;~~  
or R<sub>3</sub> and R<sub>4</sub>, together with the nitrogen atom to which R<sub>3</sub> and R<sub>4</sub> are attached, form piperidinyl.
3. (withdrawn) The compound according to claim 2 which is (2R)-2-methyl-1-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-3-[thienophen-2-ylmethyl]-amino-propan-2-ol.
4. (withdrawn) The compound according to claim 2 which is (2R)-2-methyl-1-[(pyridin-3-ylmethyl)-amino]-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propan-2-ol.
5. (withdrawn) The compound according to claim 2 which is (2R)-2-methyl-1-[(pyridin-2-ylmethyl)-amino]-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propan-2-ol.
6. (withdrawn) The compound according to claim 2 which is (2S)-1-(2-thienylmethylamino)-2-methyl-3-[3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy]propan-2-ol.
7. (withdrawn) The compound according to claim 2 which is (2S)-1-[4-(3-chlorophenoxy)-1-piperidinyl]-2-methyl-3-[3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy]propan-2-ol.
8. (withdrawn) The compound according to claim 2 which is (2S)-1-[4-(6-fluorobenzo[*d*]isoxazol-3-yl)piperidin-1-yl]-2-methyl-3-[3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy]propan-2-ol.
9. (withdrawn) The compound according to claim 2 which is (2R)-2-methyl-1-[(pyridin-4-ylmethyl)-amino]-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propan-2-ol.
10. (withdrawn) The compound according to claim 2 which is (2R)-1-[4-(6-fluorobenzo[*d*]isoxazol-3-yl)piperidin-1-yl]-3-(4-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)propan-2-ol.
11. (withdrawn) The compound according to claim 2 which is (2S)-1-(3-thienylmethylamino)-2-methyl-3-[3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy]propan-2-ol.
12. (withdrawn) The compound according to claim 2 which is (2S)-2-methyl-1-[(pyridin-3-ylmethyl)amino]-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)propan-2-ol.

13. (withdrawn) The compound according to claim 2 which is (2S)-2-methyl-1-[(pyridin-2-ylmethyl)amino]-3-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)propan-2-ol.
14. (withdrawn) The compound according to claim 2 which is (4-fluorophenyl)-(1-{2(R)-hydroxy-3-[3-(1-methyl-1H-thieno[3,2-c]pyrazol-3-yl)-phenoxy]-propyl}-piperidin-4-yl)-methanone.
15. (withdrawn) The compound according to claim 2 which is 1-(1-{2(R)-hydroxy-3-[3-(1-methyl-1H-thieno[3,2-c]pyrazol-3-yl)-phenoxy]-propyl}-piperidin-4-yl)-1,3-dihydrobenzimidazol-2-one.
16. (withdrawn) A compound according to claim 2 wherein  
R<sub>1</sub> is OH;  
R<sub>2</sub> is H;  
R<sub>3</sub> is (CH<sub>2</sub>)<sub>n</sub> Q; or  
R<sub>3</sub> and R<sub>4</sub> together with the nitrogen atom to which R<sub>3</sub> and R<sub>4</sub> are attached form piperidinyl;  
and  
n is 1.
17. (original) A compound according to claim 16 wherein Q is thienyl.
18. (original) The compound according to claim 17 which is (2R)-1-(4-thieno[2,3-d]isoxazol-3-yl-phenoxy)-3-[(thiophen-3-ylmethyl)-amino]-propan-2-ol.
19. (original) The compound of claim 17 which is (2R)-1-(4-thieno[2,3-d]isoxazol-3-yl-phenoxy)-3-[(thiophen-2-ylmethyl)-amino]-propan-2-ol.
20. (original) The compound of claim 17 which is (2R)-1-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)-3-[(thiophen-2-ylmethyl)amino]propan-2-ol.
21. (original) The compound of claim 17 which is (2R)-1-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)-3-[(thiophen-3-ylmethyl)amino]propan-2-ol.
22. (withdrawn) A compound according to claim 16 wherein Q is pyridyl.
23. (withdrawn) The compound of claim 22 which is (2R)-1-[(pyridin-4-yl)methylamino]-3-[3-thieno[2,3-d]isoxazol-3-yl-phenoxy]propan-2-ol.
24. (withdrawn) The compound of claim 22 which is (2R)-1-[(pyridin-2-ylmethyl)-amino]-3-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)-propan-2-ol.
25. (withdrawn) The compound of claim 22 which is (2R)-1-[(pyridin-3-ylmethyl)amino]-3-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)-propan-2-ol.
26. (withdrawn) A compound according to claim 16 wherein R<sub>3</sub> and R<sub>4</sub>, together with the nitrogen atom to which R<sub>3</sub> and R<sub>4</sub> are attached, form piperidinyl.
27. (withdrawn) The compound according to claim 26 which is 4-(4-chlorophenyl)-1-[(R)2-hydroxy-3-[3-(thieno[2,3-d]isoxazol-3-yl)phenoxy]propyl]piperidin-4-ol.

28. (withdrawn) The compound of claim 26 which is (2R)-1-[4-(6-fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]-3-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)-propan-2-ol.
29. (withdrawn) The compound of claim 26 which is (2R)-1-[4-(6-chlorobenzo[d]isoxazol-3-yl)piperidin-1-yl]-3-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)-propan-2-ol.
30. (withdrawn) The compound of claim 26 which is (2R)-1-[4-(6-fluorobenzo[d]isothiazol-3-yl)-piperidin-1-yl]-3-(thieno[2,3-d]isoxazol-3-yl-phenoxy)propan-2-ol.
31. (withdrawn) The compound of claim 26 which is (2R)-1-(4-benzylpiperidin-1-yl)-3-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)-propan-2-ol.
32. (withdrawn) The compound of claim 26 which is (2R)-1-piperidin-1-yl-3-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)-propan-2-ol.
33. (withdrawn) A compound according to claim 1 wherein  
R<sub>3</sub> and R<sub>4</sub>, together with the nitrogen atom to which R<sub>3</sub> and R<sub>4</sub> are attached, form piperazinyl.
34. (withdrawn) The compound of claim 33 which is (2R)-1-[4-(4-chlorophenyl)piperazin-1-yl]-3-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)propan-2-ol.
35. (withdrawn) The compound of claim 33 which is (2R)-1-[4-(2-methoxyphenyl)-piperazin-1-yl]-3-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)-propan-2-ol.
36. (withdrawn) The compound of claim 33 which is (2R)-1-[4-(2-fluorophenyl)piperazin-1-yl]-3-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)-propan-2-ol.
37. (withdrawn) The compound of claim 33 which is (2R)-1-[4-(4-fluorophenyl)piperazin-1-yl]-3-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)-propan-2-ol.
38. (withdrawn) The compound of claim 33 which is (2R)-1-[4-(2-chlorophenyl)piperazin-1-yl]-3-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)-propan-2-ol.
39. (withdrawn) The compound of claim 33 which is (2R)-1-[4-(3-chlorophenyl)piperazin-1-yl]-3-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)-propan-2-ol.
40. (withdrawn) The compound of claim 33 which is (2R)-1-[4-(4-methoxyphenyl)piperazin-1-yl]-3-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)-propan-2-ol.
41. (withdrawn) The compound of claim 33 which is (2R)-1-(4-phenylpiperazin-1-yl)-3-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)propan-2-ol.
42. (withdrawn) The compound of claim 33 which is 2-{4-[(R)-2-hydroxy-3-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)-propyl]piperazin-1-yl}benzonitrile.
43. (withdrawn) The compound of claim 33 which is (2R)-1-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)-3-[4-(2-trifluoromethylphenyl)-piperazin-1-yl]propan-2-ol.
44. (withdrawn) The compound of claim 33 which is (2R)-1-[4-(2-methoxyphenyl)piperazin-1-yl]-3-(4-thieno[2,3-d]isoxazol-3-yl-phenoxy)propan-2-ol.
45. (withdrawn) The compound of claim 33 which is 2-{4-[(R)-2-hydroxy-3-(4-thieno[2,3-d]isoxazol-3-yl-phenoxy)propyl]-piperazin-1-yl}benzonitrile.

46. (withdrawn) The compound of claim 33 which is (2S)-1-[4-(2-methoxyphenyl)piperazin-1-yl]-2-methyl-3-[3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy]propan-2-ol.
47. (withdrawn) The compound of claim 33 which is (2S)-1-[4-(2-cyanophenyl)-1-piperazinyl]-2-methyl-3-[3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy]propan-2-ol.
48. (withdrawn) The compound of claim 33 which is (2R)-1-(4-pyrimidin-2-yl-piperazin-1-yl)-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propan-2-ol.
49. (withdrawn) The compound of claim 33 which is (2R)-1-(4-pyridin-2-yl-piperazin-1-yl)-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propan-2-ol.
50. (withdrawn) The compound of claim 33 which is (2R)-1-(4-benzo[1,3]dioxol-5-ylmethyl-piperazin-1-yl)-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)propan-2-ol.
51. (withdrawn) The compound of claim 33 which is (2R)-1-[4-(6-fluoro-1H-indazol-3-yl)-piperazin-1-yl]-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propan-2-ol.
52. (withdrawn) The compound of claim 33 which is (2R)-1-[4-(5-methoxy-1H-indazol-3-yl)-piperazin-1-yl]-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propan-2-ol.
53. (withdrawn) The compound of claim 33 which is (2R)-1-(4-benzo[*d*]isothiazol-3-yl-piperazin-1-yl)-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propan-2-ol.
54. (withdrawn) The compound of claim 33 which is (2R)-1-[4-(6-fluorobenzo[*b*]thiophen-3-yl)piperazin-1-yl]-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propan-2-ol.
55. (withdrawn) The compound of claim 33 which is 3-[(R)-4-[2-hydroxy-3(3-thieno[2,3-*d*]isoxazol-3-yl)phenoxy]propyl]-piperazin-1-yl]-benzo[*d*]isoxazol-6-ol.
56. (withdrawn) The compound of claim 33 which is (2R)-1-[4-(4-methoxyphenyl)-3-methylpiperazin-1-yl]-3-[3-(thieno[2,3-*d*]isoxazol-3-yl)phenoxy]propan-2-ol.
57. (withdrawn) The compound of claim 33 which is (2R)-1-[3-(1-methyl-1H-thieno[3,2-*c*]pyrazol-3-yl)-phenoxy-3-(4-phenyl-piperazin-1-yl)-propan-2-ol.
58. (withdrawn) The compound of claim 33 which is (2R)-1-[3-(1-methyl-1H-thieno[3,2-*c*]pyrazol-3-yl)-phenoxy-3-(4-pyrimidin-2-yl-piperazin-1-yl)-propan-2-ol.
59. (withdrawn) A compound according to claim 1 wherein Q is phenyl.
60. (withdrawn) The compound of claim 59 which is (2R)-1-(4-chlorobenzylamino)-2-methyl-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propan-2-ol.
61. (withdrawn) The compound of claim 59 which is (2R)-1-[(N-benzyl-N-methyl)amino]-3-[2-thieno[2,3-*d*]isoxazol-3-yl)phenoxy]-2-propanol.
62. (withdrawn) The compound of claim 59 which is (2S)-(+)-1-benzylamino-2-methyl-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)propan-2-ol.
63. (withdrawn) The compound of claim 59 which is (2R)-(-)-1-benzylamino-2-methyl-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)propan-2-ol.

64. (withdrawn) The compound of claim 59 which is (2R)-1-(benzylmethylamino)-2-methyl-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)propan-2-ol.
65. (withdrawn) The compound of claim 59 which is (2R)-1-(4-methoxybenzylamino)-2-methyl-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propan-2-ol.
66. (withdrawn) The compound of claim 59 which is (2R)-1-(4-fluorobenzylamino)-2-methyl-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propan-2-ol.
67. (withdrawn) The compound of claim 59 which is (2R)-1-(2-fluorobenzylamino)-2-methyl-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propan-2-ol.
68. (withdrawn) The compound of claim 59 which is (2R)-2-methyl-1-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-3-(4-trifluoromethylbenzylamino)-propan-2-ol.
69. (withdrawn) The compound of claim 59 which is (2R)-2-methyl-1-[1(R)-phenylethylamino]-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propan-2-ol.
70. (withdrawn) The compound of claim 59 which is (2R)-2-methyl-1-[1(S)-phenylethylamino]-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propan-2-ol.
71. (withdrawn) The compound of claim 59 which is (2R)-1-(2-hydroxy-2-phenylethylamino)-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)propan-2-ol.
72. (withdrawn) The compound of claim 59 which is (2R)-benzyl-[2-methoxy-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)propyl]-methylamine hydrochloride.
73. (withdrawn) The compound of claim 59 which is (2R)-benzyl-[2-methoxy-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)propyl]-amine.
74. (withdrawn) The compound of claim 59 which is (2S)-1-(4-fluorobenzylamino)-2-methyl-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)propan-2-ol.
75. (withdrawn) The compound of claim 59 which is (2S)-1-(2-fluorobenzylamino)-2-methyl-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)propan-2-ol.
76. (withdrawn) The compound of claim 59 which is (2S)-1-(3-fluorobenzylamino)-2-methyl-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)propan-2-ol.
77. (withdrawn) The compound of claim 59 which is (2S)-1-(4-chlorobenzylamino)-2-methyl-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)propan-2-ol.
78. (withdrawn) The compound of claim 59 which is (2S)-1-(2-chlorobenzylamino)-2-methyl-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)propan-2-ol.
79. (withdrawn) The compound of claim 59 which is (2S)-1-(3,4-dichlorobenzylamino)-2-methyl-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)propan-2-ol.
80. (withdrawn) The compound of claim 59 which is (2S)-2-methyl-1-[1(R)-phenylethylamino]-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propan-2-ol.
81. (withdrawn) The compound of claim 59 which is (2S)-2-methyl-1-[1(S)-phenylethylamino]-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propan-2-ol.


82. (withdrawn) The compound of claim 59 which is (2S)-2-methyl-1-(4-methylbenzylamino)-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)propan-2-ol.
83. (withdrawn) The compound of claim 59 which is (2S)-1-(4-methoxybenzylamino)-2-methyl-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)propan-2-ol.
84. (withdrawn) The compound of claim 59 which is (2S)-1-(2-methoxybenzylamino)-2-methyl-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)propan-2-ol.
85. (withdrawn) The compound of claim 59 which is (2S)-1-(benzylmethylamino)-2-methyl-3-[3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy]propan-2-ol.
86. (withdrawn) The compound of claim 59 which is (2S)-1-(3,4-difluorobenzylamino)-2-methyl-3-[3-(thieno[2,3-*d*]isoxazol-3-yl)phenoxy]propan-2-ol.
87. (withdrawn) The compound of claim 59 which is (2R)-1-(2-methoxybenzylamino)-2-methyl-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propan-2-ol.
88. (original) A compound according to claim 1 wherein Q is furanyl.
89. (original) The compound of claim 88 which is (2R)-1-[(furan-2-ylmethyl)-amino]-2-methyl-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propan-2-ol.
90. (original) The compound of claim 88 which is (2R)-1-[(furan-2-ylmethyl)amino]-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propan-2-ol.
91. (original) The compound of claim 88 which is (2R)-1-[(furan-2-ylmethyl)-amino]-3-(4-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)propan-2-ol.
92. (original) The compound of claim 88 which is (2S)-1-[(furan-2-ylmethyl)amino]-2-methyl-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)propan-2-ol.
93. (original) A compound according to claim 1 wherein R<sub>3</sub> is indanyl.
94. (original) The compound of claim 93 which is (2R)-1-(indan-1-ylamino)-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propan-2-ol.
95. (original) The compound of claim 93 which is (2R)-1-(indan-2-ylamino)-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propan-2-ol.
96. (withdrawn) A compound according to claim 1 wherein Q is naphthyl.
97. (withdrawn) The compound of claim 96 which is (2R)-1-[(naphthalen-1-ylmethyl)amino]-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)propan-2-ol.
98. (withdrawn) The compound of claim 96 which is (2R)-2-methyl-1-[(naphthalen-1-ylmethyl)amino]-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propan-2-ol.
99. (withdrawn) The compound of claim 96 which is (2R)-1-[(naphthalen-1-ylmethyl)-amino]-3-(4-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propan-2-ol.
100. (withdrawn) The compound of claim 96 which is (2S)-2-methyl-1-[(naphthalen-1-ylmethyl)amino]-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)propan-2-ol.

101. (withdrawn) A compound according to claim 1 wherein R<sub>3</sub> and R<sub>4</sub>, together with the nitrogen atom to which R<sub>3</sub> and R<sub>4</sub> are attached, form 1,2,3,4-tetrahydroisoquinoliny.
102. (withdrawn) The compound of claim 101 which is (±)-1-(3,4-dihydro-1H-isoquinolin-2-yl)-3-[2-(thieno[2,3-*d*]isoxazol-3-yl)phenoxy]-2-propanol.
103. (withdrawn) The compound of claim 101 which is (2R)-1-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)-3-[3-(thieno[2,3-*d*]isoxazol-3-yl)phenoxy]propan-2-ol.
104. (withdrawn) The compound of claim 101 which is (2R)-1-(3,4-dihydro-1H-isoquinolin-2-yl)-3-[2-(thieno[2,3-*d*]isoxazol-3-yl)phenoxy]-2-propanol.
105. (withdrawn) The compound of claim 101 which is (2R)-1-(3,4-dihydro-1H-isoquinolin-2-yl)-3-[3-(1-methyl-1H-thieno[3,2-*c*]pyrazol-3-yl)-phenoxy]-propan-2-ol.
106. (withdrawn) A compound according to claim 1, wherein R<sub>3</sub> and R<sub>4</sub>, together with the nitrogen atom to which R<sub>3</sub> and R<sub>4</sub> are attached, form 1,2,3,4-tetrahydro-β-carboliny.
107. (withdrawn) The compound of claim 106 which is (2R)-1-(1,2,3,4-tetrahydro-β-carbolin-2-yl)-3-[3-thieno[2,3-*d*]isoxazol-3-yl)phenoxy]propan-2-ol.
108. (withdrawn) A compound according to claim 1, wherein R<sub>3</sub> and R<sub>4</sub>, together with the nitrogen atom to which R<sub>3</sub> and R<sub>4</sub> are attached, form 4,5,6,7-tetrahydrothieno[3,2-*c*]pyridiny.
109. (withdrawn) The compound of claim 108 which is (2R)-1-(6,7-dihydro-4H-thieno[3,2-*c*]pyridin-5-yl)-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)propan-2-ol.
110. (withdrawn) The compound of claim 108 which is (2R)-1-(6,7-dihydro-4H-thieno[3,2-*c*]pyridin-5-yl)-3-(4-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)propan-2-ol.
111. (withdrawn) A compound according to claim 1, wherein R<sub>3</sub> and R<sub>4</sub>, together with the nitrogen atom to which R<sub>3</sub> and R<sub>4</sub> are attached, form 8-aza-bicyclo[3.2.1]octane.
112. (withdrawn) The compound of claim 111 which is (2R)-1-(3-benzo[*d*]isoxazol-3-yl-8-azabicyclo[3.2.1]oct-8-yl)-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)propan-2-ol.
113. (original) A compound according to claim 1, wherein R<sub>3</sub> is adamantyl.
114. (original) The compound of claim 113 which is (2R)-1-(adamantan-1-ylamino)-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propan-2-ol.
115. (withdrawn) A compound according to claim 1, wherein Q is cyclohexyl.
116. (withdrawn) compound of claim 115 which is (2R)-1-(cyclohexylmethyl-amino)-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propan-2-ol.
117. (withdrawn) A compound according to claim 1, wherein Q is benzimidazolyl.
118. (withdrawn) The compound of claim 117 which is (2R)-1-[(1H-benzimidazol-2-ylmethyl)amino]-3-[3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy]propan-2-ol.
119. (original) A compound according to claim 1, wherein R<sub>3</sub> is 1,2,3,4-tetrahydronaphthyl.



120. (original) The compound of claim 119 which is (2R)-1-(1,2,3,4-tetrahydronaphthalen-1-ylamino)-3-[3-thieno[2,3-d]isoxazol-3-yl]phenoxy]propan-2-ol.


121. (withdrawn) A compound of formula



wherein X is N(CH<sub>3</sub>) or O; and

R<sub>1</sub> is H or C<sub>1-6</sub>alkyl.

122. (withdrawn) A compound of formula




wherein X is N(CH<sub>3</sub>) or O;

R<sub>1</sub> is H or C<sub>1-6</sub>alkyl; and

R<sub>2</sub> is CH<sub>3</sub>, F, p-bromobenzene, p-nitrobenzene, or p-methylbenzene.

123. (withdrawn) A method for antagonizing the effects of dopamine at the D<sub>4</sub> receptor comprising administering a compound according to claim 1 to a patient in need thereof.
124. (original) A composition comprising a compound according to claim 1 in admixture with an inert carrier.
125. (original) The composition according to claim 124 wherein said inert carrier is a pharmaceutical carrier.
126. (withdrawn) A method of treating psychoses comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1.
127. (withdrawn) A method of treating Attention Deficit Hyperactivity Disorder comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1.
128. (withdrawn) A method of treating Obsessive-Compulsive Disorder comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1.
129. (withdrawn) A method of treating Substance Abuse comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1.

130. (withdrawn) A method of treating Substance Dependence comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1.
131. (withdrawn) A method of treating Parkinson's Disease comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1.
132. (withdrawn) A method of treating Parkinsonism comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1.
133. (withdrawn) A method of treating Tardive Dyskinesia comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1.
134. (withdrawn) A method of treating Gilles de la Tourette Syndrome comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1.
135. (withdrawn) A method of treating Conduct Disorder comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1.
136. (withdrawn) A method of treating Oppositional Defiant Disorder comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1.
137. (currently amended) A method of making a compound of formula I



a pharmaceutically acceptable salt or stereoisomer thereof,

wherein

X is N(CH<sub>3</sub>) or O;

R<sub>1</sub> is OH or C<sub>1-6</sub> alkoxy;

R<sub>2</sub> is H or C<sub>1-6</sub> alkyl;

R<sub>3</sub> is (CH<sub>2</sub>)<sub>n</sub> Q, CH<sub>2</sub>CH(OH)Q, CH(CH<sub>3</sub>)Q, 1,2,3,4-tetrahydronaphthyl, indanyl, or adamantyl, wherein

Q is thienyl, phenyl, or furanyl, naphthyl, pyridyl, indolyl, indazolyl, cyclohexyl, 1,2-methylenedioxyphenyl, cyclohexenyl, 1H-pyrazole[4,3-c]pyridyl, and

Q is optionally substituted with one or two moieties independently selected from halo, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxy, hydroxy, S(O)<sub>2</sub>NH<sub>2</sub>, trifluoromethyl, or cyano, and n is 1 or 2; and

R<sub>4</sub> is H or C<sub>1-6</sub> alkyl; or


~~— R<sub>3</sub> and R<sub>4</sub>, together with the nitrogen atom to which R<sub>3</sub> and R<sub>4</sub> are attached, form 1,4 dioxo-8-  
 aze-spiro[4.5]decanyl, piperazinyl, morpholinyl, piperidinyl, pyrrolidinyl, azocanyl, 1,2,3,4-  
 tetrahydroisoquinolinyl, 1,2,3,4 tetrahydro-β-carbolinyl, 4,5,6,7 tetrahydrothienyl[3,2-  
 e]pyridyl, or 8-aza-bicyclo[3.2.1.]octane, each of which may be mono- or independently di-  
 substituted with halo, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxy, C(O)phenyl, OH, CN, O-phenyl or (CH<sub>2</sub>)<sub>m</sub>Z,~~

~~Z is benzisoxazolyl, indazolyl, benzisothiazolyl, benzothienyl, pyrimidinyl,  
 pyridyl, 1,2-methylenedioxyphenyl, or phenyl, and~~


~~Z, CH(OH)phenyl or O-phenyl are optionally substituted with one or two  
 moieties independently selected from halo, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxy,  
 hydroxy, trifluoromethyl, S(O)<sub>2</sub>NH<sub>2</sub>, or cyano, and~~

~~m is 0 or 1;~~

comprising the step of coupling a reagent of formula II




wherein X and R<sub>2</sub> are as defined in formula I;  
 with a reagent of formula III



wherein  $R_3$  and  $R_4$  are as defined in formula I;  
to provide the compound of formula I.

138. (currently amended) A method of making a compound of formula I



a pharmaceutically acceptable salt or stereoisomer thereof,

wherein

X is N(CH<sub>3</sub>) or O;

R<sub>1</sub> is OH or C<sub>1-6</sub> alkoxy;

R<sub>2</sub> is H or C<sub>1-6</sub> alkyl;

R<sub>3</sub> is (CH<sub>2</sub>)<sub>n</sub> Q, CH<sub>2</sub>CH(OH)Q, CH(CH<sub>3</sub>)Q, 1,2,3,4-tetrahydronaphthyl, indanyl, or adamantyl,

wherein

Q is thienyl, phenyl, or furanyl, naphthyl, pyridyl, indolyl, indazolyl, cyclohexyl, 1,2-methylenedioxyphenyl, cyclohexenyl, 1H-pyrazolo[4,3-c]pyridyl, and

Q is optionally substituted with one or two moieties independently selected from halo,

C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxy, hydroxy, S(O)<sub>2</sub>NH<sub>2</sub>, trifluoromethyl, or cyano, and

n is 1 or 2; and

R<sub>4</sub> is H or C<sub>1-6</sub> alkyl; or


~~R<sub>3</sub> and R<sub>4</sub>, together with the nitrogen atom to which R<sub>3</sub> and R<sub>4</sub> are attached, form 1,4-dioxo-8-azo-spiro[4.5]decanyl, piperazinyl, morpholinyl, piperidinyl, pyrrolidinyl, azocanyl, 1,2,3,4-tetrahydroisoquinolinyl, 1,2,3,4-tetrahydro-β-carbolinyl, 4,5,6,7-tetrahydrothienyl[3,2-c]pyridyl, or 8-aza-bicyclo[3.2.1]octane, each of which may be mono- or independently di-substituted with halo, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxy, C(O)phenyl, OH, CN, O-phenyl or (CH<sub>2</sub>)<sub>m</sub>Z,~~

~~Z is benzisoxazolyl, indazolyl, benzisothiazolyl, benzothienyl, pyrimidinyl, pyridyl, 1,2-methylenedioxyphenyl, or phenyl, and~~

~~Z, CH(OH)phenyl or O-phenyl are optionally substituted with one or two moieties independently selected from halo, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxy, hydroxy, trifluoromethyl, S(O)<sub>2</sub>NH<sub>2</sub>, or cyano, and~~

~~m is 0 or 1;~~


comprising the step of coupling a compound of formula II



wherein X and R<sub>2</sub> are as defined in formula I; and

R<sub>5</sub> is CH<sub>3</sub>, CF<sub>3</sub>, F, p-bromobenzene, p-nitrobenzene, or p-methylbenzene;


with a reagent of formula III



wherein R<sub>3</sub> and R<sub>4</sub> are as defined in formula I;

to provide the compound of formula I.

139. (currently amended) A method of making a compound of formula I



a pharmaceutically acceptable salt or stereoisomer thereof,

wherein

X is N(CH<sub>3</sub>) or O;

R<sub>1</sub> is OH or C<sub>1-6</sub> alkoxy;

R<sub>2</sub> is H or C<sub>1-6</sub> alkyl;

R<sub>3</sub> is (CH<sub>2</sub>)<sub>n</sub> Q, CH<sub>2</sub>CH(OH)Q, CH(CH<sub>3</sub>)Q, 1,2,3,4-tetrahydronaphthyl, indanyl, or adamantyl,

wherein

Q is thienyl, ~~phenyl, or furanyl, naphthyl, pyridyl, indolyl, indazolyl, cyclohexyl, 1,2-methylenedioxyphenyl, cyclohexenyl, 1H-pyrazolo[4,3-c]pyridyl, and~~

Q is optionally substituted with one or two moieties independently selected from halo,

C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxy, hydroxy, S(O)<sub>2</sub>NH<sub>2</sub>, trifluoromethyl, or cyano, and

n is 1 or 2; and

$R_4$  is H or  $C_{1-6}$  alkyl; or


~~$R_3$  and  $R_4$ , together with the nitrogen atom to which  $R_3$  and  $R_4$  are attached, form 1,4 dioxo-8-azo spiro[4.5]decanyl, piperazinyl, morpholinyl, piperidinyl, pyrrolidinyl, azocanyl, 1,2,3,4-tetrahydroisoquinolinyl, 1,2,3,4-tetrahydro- $\beta$ -carbolinyl, 4,5,6,7-tetrahydrothienyl[3,2-e]pyridyl, or 8-aza bicyclo[3.2.1]octane, each of which may be mono or independently disubstituted with halo,  $C_{1-6}$  alkyl,  $C_{1-6}$  alkoxy,  $C(O)$ phenyl, OH, CN, O-phenyl or  $(CH_2)_mZ$ ,~~

~~$Z$  is benzisoxazolyl, indazolyl, benzisothiazolyl, benzothienyl, pyrimidinyl, pyridyl, 1,2-methylenedioxyphenyl, or phenyl, and~~

~~$Z$ ,  $CH(OH)$ phenyl or O-phenyl are optionally substituted with one or two moieties independently selected from halo,  $C_{1-6}$  alkyl,  $C_{1-6}$  alkoxy, hydroxy, trifluoromethyl,  $S(O)_2NH_2$ , or cyano, and~~


~~$m$  is 0 or 1;~~

comprising the step of coupling a reagent of formula II



wherein X is as defined in formula I;

with a reagent of formula III



wherein  $R_2$ ,  $R_3$ , and  $R_4$  are as defined in formula I;

to provide the compound of formula I.